Biogen Reports Second Quarter 2016 Revenues of $2.9 Billion
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Biogen's (BIIB) Big Moves Signal Future Sale
July 21, 2016 1:11 PM EDTBiogen (NASDAQ: BIIB) made a number of key changes Thursday and that has investors thinking a takeover could be in the company's future. The speculation has shares up over 7%.
First, Biogen announced that long-time CEO, George Scangos, is stepping down. Also, major... More
Biogen (BIIB) Announces 3 Major Changes to Get the Stock Moving Higher - BMO Capital
July 21, 2016 8:44 AM EDTBMO Capital analyst M. Ian Somaiya weighed in on Biogen (NASDAQ: BIIB) noting 3 major change were announced this morning to get the stock moving higher:
1) departure of CEO, George Scangos,
2) major cost cutting initiatives that led to 2016 non-GAAP EPS guidance being raised to $19.70-20.00 from... More
Scangos Retirement May Be Precursor to Big M&A Plans at Biogen (BIIB) - Leerink
July 21, 2016 8:24 AM EDTLeerink Partners analyst Geoffrey Porges weighed in on Biogen (NASDAQ: BIIB) after the company reported earnings, announced a $5bn share buyback as well as the retirement of CEO George Scangos.
"We expect BIIBs stock to be modestly higher following these results, but... More
Biogen (BIIB) Approves $5B Stock Buyback Program
July 21, 2016 7:06 AM EDTBiogen (NASDAQ: BIIB) announced that its Board of Directors authorized a program to repurchase up to $5 billion of the Companys common stock. Biogen currently expects that purchases will be executed over the next three years. This share repurchase program is in addition to the... More
